• PAA17 PARENTS OF ASTHMATIC CHILDREN WERE ACCURATE REPORTERS OF URGENT HEALTH SERVICES USE— A RETROSPECTIVE AGREEMENT ANALYSIS

    May 1, 2007, 00:00

  • PUK10 COST ANALYSIS OF PRE-DIALYSIS CHRONIC KIDNEY DISEASE-AN EMPLOYER'S PERSPECTIVE

    May 1, 2007, 00:00

  • PGI11 RELATIONSHIP BETWEEN GASTROESOPHAGEAL REFLUX DISEASE SYMPTOMS AND COSTS-A DATABASE STUDY IN A US COHORT

    May 1, 2007, 00:00

  • PIN8 BURDEN OF HERPES ZOSTER AND HEALTH AND BUDGET IMPACT OF A VACCINATION PROGRAM

    May 1, 2007, 00:00

  • Abstracts Index

    May 1, 2007, 00:00

  • PCN54 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH AXITINIB (AG-013736)

    May 1, 2007, 00:00

  • PRS2 CLINICAL OUTCOMES OF PATIENTS HOSPITALIZED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) EXACERBATIONS IN SINGAPORE

    May 1, 2007, 00:00

  • PCASE11 SYNAGIS 2005–2006 SEASON

    May 1, 2007, 00:00

  • PND23 PSYCHOMETRIC EVALUATION OF FIVE MIGRAINE SPECIFIC HEALTH RELATED QUALITY OF LIFE INSTRUMENTS

    May 1, 2007, 00:00

  • PHM1 A COMPARISON OF INPATIENT OUTCOMES BETWEEN SICKLE CELL DISEASE AND NON-SICKLE CELL DISEASE PATIENTS UNDERGOING HIGH-VOLUME SURGICAL PROCEDURES

    May 1, 2007, 00:00

  • PND1 ASSESSING THE NET CLINICAL BENEFIT AND ABSOLUTE RISK REDUCTION OF DISEASE MODIFYING DRUGS IN RELAPSING REMITTING MULTIPLE SCLEROSIS

    May 1, 2007, 00:00

  • PIN28 BUDGET IMPACT AND UTILISATION OF ANTIBIOTICS WITHIN SLOVAKIA

    May 1, 2007, 00:00

  • PCV27 CLINICAL AND ECONOMIC BURDEN OF NONADHERANCE TO LIPID-LOWERING AND ANTIHYPERTENSIVE THERAPY IN A HYPERTENSIVE POPULATION

    May 1, 2007, 00:00

  • PMC8 CREATING KNOWLEDGE ABOUT ADVERSE DRUG REACTIONS-A CRITICAL ANALYSIS OF THE DANISH REPORTING SYSTEM FROM 1968 TO 2005

    May 1, 2007, 00:00

  • PIN1 COST-EFFECTIVENESS OF ACUTE AND CHRONIC RHINOSINUSITIS AT THE MEXICAN INSTITUTE OF SOCIAL SECURITY (IMSS)

    May 1, 2007, 00:00

  • PHP15 STUDYING THE IMPACT OF CO-PAYMENT DIFFERENTIAL ON GENERIC DISPENSING RATE IN A MANAGED CARE POPULATION

    May 1, 2007, 00:00

  • PCN50 CHALLENGES AND LIMITATIONS OF IDENTIFYING PRESCRIPTION TREATMENT PATTERNS FOR PATIENTS WITH METASTATIC BREAST CANCER USING COMMERCIALLY INSURED CLAIMS DATABASES

    May 1, 2007, 00:00

  • PHP35 BREAK-EVEN COST ANALYSIS OF MEDICATION THERAPY MANAGEMENT PROGRAMS FOCUSING ON ADVERSE DRUG EVENT PREVENTION

    May 1, 2007, 00:00

  • PIN25 DIRECT COSTS OF ANEMIA AMONG PATIENTS TREATED WITH ZIDOVUDINE

    May 1, 2007, 00:00

  • PHP8 RACIAL/ETHNIC DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AND OUT-OF-POCKET COSTS

    May 1, 2007, 00:00

  • PCV59 EFFECTIVENESS OF OUTPATIENT CLOPIDOGREL TREATMENT IN PREVENTING CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING STENTING FOR ACS- A RETROSPECTIVE CLAIMS DATABASE ANALYSIS

    May 1, 2007, 00:00

  • PIN23 DETERMINANTS OF TOTAL HOSPITAL COSTS AMONG INPATIENTS WITH CANDIDEMIA

    May 1, 2007, 00:00

  • PAA8 QUALITY-ADJUSTED LENGTH OF STAY ANALYSIS OF HOSPITALIZED PATIENTS WITH ASTHMA OR COPD TREATED WITH LEVALBUTEROL OR RACEMIC ALBUTEROL

    May 1, 2007, 00:00

  • PMH22 HEALTH CARE COSTS AND RESOURCE USE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER-A COMPARISON BETWEEN ESCITALOPRAM AND OTHER ANTIDEPRESSANTS

    May 1, 2007, 00:00

  • PAA21 IS CURE WORSE THAN THE DISEASE?

    May 1, 2007, 00:00

  • PMC28 JUSTIFYING THE USE OF COST MINIMIZATION ANALYSIS- REPORTING COMPARATORS' EQUIVALENCE

    May 1, 2007, 00:00

  • PCV18 PERIPHERAL ARTERIAL DISEASE IN DIABETIC PATIENTS- A COST-EFFECTIVENESS ANALYSIS COMPARING MAGNETIC RESONANCE ANGIOGRAPHY WITH DIGITAL SUBTRACTION ANGIOGRAPHY

    May 1, 2007, 00:00

  • PHP26 MORE POLICY INITIATIVES IN THE AUSTRALIAN NATIONAL REIMBURSEMENT SYSTEM THAT WILL REDUCED COSTS DRAMATICALLY

    May 1, 2007, 00:00

  • PIH4 THE DIRECT AND INDIRECT COST BURDEN OF TREATED UTERINE FIBROIDS

    May 1, 2007, 00:00

  • PCV41 UTILIZATION AND COMPLIANCE OF CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF HYPERTENSION IN THE LOUISIANA MEDICAID PROGRAM

    May 1, 2007, 00:00

  • PDB33 VALIDATION OF THE 25-ITEM NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE (VFQ-25) IN PATIENTS WITH DIABETIC RETINOPATHY

    May 1, 2007, 00:00

  • PND16 ASSOCIATION OF LONG-TERM MIGRAINE PREVENTIVE MEDICATION USE AND RESOURCE UTILIZATION/PRODUCTIVITY LOSS- RESULTS FROM THE AMERICAN MIGRAINE PREVALENCE AND PREVENTION (AMPP) STUDY

    May 1, 2007, 00:00

  • PCV70 MOBILE PHONE MESSAGE VERSUS POSTAL REMINDERS TO INCREASE TREATMENT ADHERENCE AFTER LIPID LOWERING THERAPY AMONG HYPERLIPIDEMIC PATIENTS IN PRIMARY CARE

    May 1, 2007, 00:00

  • PMH5 A COMPARISON OF TREATMENT-EMERGENT DIABETES AMONG ATYPICAL AND TYPICAL ANTIPSYCHOTIC USERS- USING A BIVARIATE PROBIT MODEL

    May 1, 2007, 00:00

  • PMH30 HEALTH CARE BURDEN OF PATIENTS WITH ALCOHOL DEPENDENCE SYNDROME

    May 1, 2007, 00:00

  • PHP40 EFFECTS OF EDUCATIONAL INTERVENTION ON PRESCRIPTION WRITING IN PUBLIC AND PRIVATE HOSPITALS IN BENIN CITY, NIGERIA

    May 1, 2007, 00:00

  • PIN21 THE CLINICAL AND ECONOMIC BURDEN OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS DUE TO STAPHYLOCOCCUS AUREUS- FINDINGS FROM A NATIONAL DATABASE

    May 1, 2007, 00:00

  • PMC27 EFFECT OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) ON THE HEALTH SERVICE UTILIZATION FOR PATIENTS WITH CHRONIC DISEASES

    May 1, 2007, 00:00

  • PCV61 DIFFERENCES IN ANTIBIOTICS PRESCRIBED BY PHYSICIANS WITH HIGH AND LOW INFECTION RATES APPLIED TO PATIENTS UNDERGOING CARDIOVASCULAR SURGERY

    May 1, 2007, 00:00

  • PCN57 PATIENT REPORTED OUTCOMES IN LABELING FOR ONCOLOGY PRODUCTS- REVIEW OF FDA AND EMEA LABELS

    May 1, 2007, 00:00

  • PIN4 TREATMENT FAILURE AMONG COMMUNITY ACQUIRED PNEUMONIA (CAP) PATIENTS TREATED WITH LEVOFLOXACIN OR MACROLIDES IN AN OUTPATIENT SETTING

    May 1, 2007, 00:00

  • PUK11 MEDICAL AND WORK PRODUCTIVITY COSTS BEFORE AND AFTER DIAGNOSIS OF ANEMIA IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS

    May 1, 2007, 00:00

  • PDB20 COMPARISON OF ROSIGLITAZONE VERSUS PIOGLITAZONE INTRODUCTION AND ASSOCIATED HEALTH CARE UTILIZATION IN TYPE 2 DIABETES MEDICAID ENROLLEES

    May 1, 2007, 00:00

  • PHP42 CORRELATION BETWEEN COLLEGE STUDENT ACTIVITIES AND TWO PRODUCTIVITY MEASUREMENTS

    May 1, 2007, 00:00

  • PQ3 A DECISION TREE APPROACH TO ESTIMATING COST SAVINGS OF PAY FOR PERFORMANCE PROGRAMS IN A PPO SETTING

    May 1, 2007, 00:00

  • OB2 THE COST OF THE METABOLIC SYNDROME IN THE ELDERLY- FINDINGS FROM THE CARDIOVASCULAR HEALTH STUDY

    May 1, 2007, 00:00

  • MH2 COMPARISON OF HEALTH CARE COSTS AND HOSPITALIZATION DAYS OF ELDERLY MAJOR DEPRESSIVE DISORDER PATIENTS TREATED WITH ESCITALOPRAM AND OTHER ANTIDEPRESSANTS

    May 1, 2007, 00:00

  • PCN45 A PRACTICAL AND USEFUL COMBINATION OF MEASURES FOR ASSESSING THE COST-UTILITY OF TWO MAJOR TREATMENT STRATEGIES FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD- RESOURCE INTENSITY WEIGHTS (RIWS) AND THE HEALTH UTILITIES INDEX (HUI ...

    May 1, 2007, 00:00

  • PCN39 GAP BETWEEN INPATIENT TREATMENT COST OF AND MORTALITY DUE TO BREAST CANCER IN HUNGARY

    May 1, 2007, 00:00

  • PEY6 THE RELATIVE COST-EFFECTIVENESS OF MULTIFOCAL INTRAOCULAR LENSES

    May 1, 2007, 00:00

  • PCV9 ISOLATED SYSTOLIC HYPERTENSION IN A COHORT OF INNER CITY MINORITY PATIENTS

    May 1, 2007, 00:00

  • PEY2 PREVALENCE OF GLAUCOMATOUS RISK FACTORS IN PATIENTS FROM A MANAGED-CARE SETTING- A PILOT EVALUATION

    May 1, 2007, 00:00

  • PRS9 ESTIMATED COST SAVINGS ASSOCIATED WITH THE USE OF A NEW TASTE-MASKED ORAL CLARITHROMYCIN PREPARATION FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS IN CHILDREN IN GERMANY

    May 1, 2007, 00:00

  • PIN39 CULTURAL ADAPTATION AND VALIDATION OF A HEALTHRELATED QUALITY OF LIFE QUESTIONNAIRE (HRQOL) FOR ENGLISH-SPEAKING HEPATITIS B PATIENTS IN SINGAPORE

    May 1, 2007, 00:00

  • PMH48 PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF ATOMOXETINE USING DISCRETE CHOICE ANALYSIS- UK PARENTS PERSPECTIVE

    May 1, 2007, 00:00

  • PCV49 DEVELOPMENT OF AN INTERACTIVE MODEL TO PREDICT LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL) REDUCTION AND LDL GOAL ATTAINMENT ASSOCIATED WITH STATIN USE IN ROUTINE CLINICAL PRACTICE

    May 1, 2007, 00:00

  • PND19 DEVELOPING A MIGRAINE QUALITY OF CARE MEASUREMENT SET

    May 1, 2007, 00:00

  • PGI3 CONSTIPATION IN PERSONS RECEIVING HOSPICE CARE- PRELIMINARY ESTIMATES

    May 1, 2007, 00:00

  • PCN26 FIRST-, SECOND- AND THIRD-LINE CHEMOTHERAPY FOR NONSMALL CELL LUNG CANCER- PATTERNS OF CARE AND COST

    May 1, 2007, 00:00

  • PCV37 THE IMPACT OF CARE GAP IN MANAGING HIGH CARDIOVASCULAR RISK PATIENTS-A CANADIAN POPULATION ANALYSIS

    May 1, 2007, 00:00

  • PUK1 A RETROSPECTIVE COMPARATIVE ANALYSIS OF TREATMENT OUTCOMES OF ALPHA-BLOCKERS IN THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA WITHIN A MANAGED CARE POPULATION

    May 1, 2007, 00:00

  • PAA18 DATA EXTRACTION METHODS, ECONOMETRIC MODELING AND FACTORIAL ANALYSIS REVEAL CLINICALLY IMPORTANT PATIENT PROFILES IN CHRONIC ASTHMA

    May 1, 2007, 00:00

  • A Cost-Effectiveness Decision Model for Antiepileptic Drug Treatment in Newly Diagnosed Epilepsy Patients

    May 1, 2007, 00:00

  • PPN12 PETS, PEOPLE AND DEMAND FOR ETODOLAC IN THE UNITED STATES OF AMERICA

    May 1, 2007, 00:00

  • PST1 EPIDEMIOLOGY AND ECONOMIC BURDEN OF STROKE-RELATED RISK FACTORS-A SYSTEMATIC LITERATURE REVIEW

    May 1, 2007, 00:00

  • PMC35 THE ISSUES THAT ARISE DURING THE TRANSLATION OF IVRS (INTERACTIVE VOICE RESPONSE SYSTEM) EPRO SCRIPTS

    May 1, 2007, 00:00

  • PHP24 COMPARING MEDICATION ADHERENCE AND WASTAGE AMONG THREE DIFFERENT RETAIL PROGRAMS

    May 1, 2007, 00:00

  • PMH31 DRUG COST DEVELOPMENT OF CITALOPRAM AND FLUOXETINE FOLLOWING THE INTRODUCTION OF GENERIC SUBSTITUTION IN FINLAND

    May 1, 2007, 00:00

  • PAA9 A 4-YEAR ASSESSMENT OF SEVERE AND NON-SEVERE ASTHMA IN A REAL-WORLD SETTING

    May 1, 2007, 00:00

  • PHP29 REGULATION OF DRUG EXPENDITURES IN EUROPEAN COUNTRIES

    May 1, 2007, 00:00

  • PND26 MEASUREMENT OF QUALITY OF LIFE IN RESTLESS LEGS SYNDROME

    May 1, 2007, 00:00

  • CASE 1 REVIEWING THE REIMBURSEMENT STATUS OF PHARMACEUTICALS—EXPERIENCES FROM SWEDEN

    May 1, 2007, 00:00

  • PPN17 QUANTIFYING HEALTH RELATED QUALITY OF LIFE IN A CHRONIC PAIN POPULATION- PRELIMINARY RESULTS

    May 1, 2007, 00:00

  • PHP25 TRENDS IN OUT OF POCKET COST BURDEN FOR PATIENTS WITH CHRONIC CONDITIONS

    May 1, 2007, 00:00

  • PRS12 PROPENSITY OF PRESCRIBING FLUTICASONE/SALMETEROL COMBINATION IN A HIGH RISK MEDICAID POPULATION

    May 1, 2007, 00:00

  • PHP18 BENEFICIARY OUT-OF-POCKET-A CROSS-SECTIONAL PILOT STUDY IN THE SAUDI MINISTRY OF HEALTH HOSPITAL OUTPATIENT CLINICS

    May 1, 2007, 00:00

  • PDB15 TREATMENT COSTS ATTRIBUTABLE TO OVERWEIGHT/OBESE IN PATIENTS WITH DIABETES MELLITUS IN THE U.S.ADULT POPULATION

    May 1, 2007, 00:00

  • PCV57 HOW INFLUENTIAL ARE CLINICAL GUIDELINES FOR THE EVALUATION OF ACUTE CARDIAC SYMPTOMS? METHODOLOGY FOR THE INVESTIGATION OF NATIONAL CORONARY DISEASE IDENTIFICATION (INCIDENT)

    May 1, 2007, 00:00

  • PCN13 COST-EFFECTIVENESS ANALYSIS OF DOCETAXEL VERSUS OTHER REGIMENS IN THE ADJUVANT THERAPY OF EARLY AND LOCALLY ADVANCED BREAST CANCER IN POLAND

    May 1, 2007, 00:00

  • PCV29 PHARMACOECONOMIC ANALYSIS OF EXTENDED PROPHYLAXIS BY ENOXAPARIN AFTER HIP JOINT REPLACEMENT

    May 1, 2007, 00:00

  • PUK4 HAEMOGLOBIN FLUCTUATIONS IN HAEMODIALYSIS PATIENTS RECEIVING INTRAVENOUS EPOETIN ALFA OR INTRAVENOUS DARBEPOETIN ALFA

    May 1, 2007, 00:00

  • PSM3 ESTIMATING THE INCIDENCE AND PREVALENCE OF SMOKING RELATED MORBIDITIES USING PROXY VALUES

    May 1, 2007, 00:00

  • PCASE13 OTC PROGRAM FOR COMMON, ROUTINE AILMENTS DESIGNED TO LOWER THE BURDEN ON PROVIDERS AND TO SUBSTITUTE LESS EXPENSIVE OTC MEDICATIONS FOR MORE COSTLY PRESCRIPTION MEDICATIONS-A CASE STUDY OF THE UNITED STATES NAVAL HOSPITAL IN KEFLAVI ...

    May 1, 2007, 00:00

  • PAA24 ASTHMA CONTROL AND HEALTH-RELATED QUALITY OF LIFE IN CHILDREN

    May 1, 2007, 00:00

  • PMC23 CONSISTENCY OF MINIMAL IMPORTANT DIFFERENCES FOR MAPPED UTILITY INSTRUMENTS IN FOUR MAJOR PATIENT GROUPS

    May 1, 2007, 00:00

  • PHM7 COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSES ROUTINELY USED IN CLINICAL PRACTICE IN DEPARTMENT OF DEFENSE BENEFICIARIES

    May 1, 2007, 00:00

  • CS4 A METHODOLOGY FOR PROJECTING DISEASE PREVALENCE, TREATMENT, AND EXPENDITURES FOR THE US EMPLOYERINSURED POPULATION

    May 1, 2007, 00:00

  • PDB12 RESOURCE UTILIZATION AND ECONOMIC COST OF CARE BASED ON A RANDOMIZED TRIAL OF V.A.C.® THERAPY IN THE TREATMENT OF DIABETIC FOOT ULCER WOUNDS

    May 1, 2007, 00:00

  • PCV15 NEW DIAGNOSIS OF HYPERTENSION AMONG CELECOXIB AND NON-SELECTIVE NSAID USERS-A POPULATION-BASED COHORT STUDY

    May 1, 2007, 00:00

  • PCV54 PROJECTED COST SAVINGS COMPARISON TO MANAGED CARE ORGANIZATIONS FOR THE YEAR FOLLOWING GENERIC SIMVASTATIN AND PRAVASTATIN AVAILABILITY IN THE US

    May 1, 2007, 00:00

  • PDB6 RACIAL DIFFERENCES IN HOSPITALIZATIONS ASSOCIATED WITH MEDICATION USE IN MEDICAID ENROLLEES WITH TYPE 2 DIABETES

    May 1, 2007, 00:00

  • PHP33 PRELIMINARY EFFECTS OF A NEW NURSE-PHARMACIST CLINICAL PREVENTION PROGRAM ON MEDICATION USE

    May 1, 2007, 00:00

  • PAR11 ECONOMIC EVALUATION OF BIOLOGIC RESPONSE MODIFIER SPECIALTY PHARMACY PRIOR AUTHORIZATION PROGRAM

    May 1, 2007, 00:00

  • PGI16 VALIDATION OF GASTROINTESTINAL QUALITY OF LIFE INDEX FOR ASSESSMENT OF GALLSTONE-RELATED SYMPTOMS

    May 1, 2007, 00:00

  • PHM2 STUDY OF ANEMIA IN LONG-TERM CARE (SALT)- RELATIONSHIP BETWEEN ANEMIA AND FALLS IN THE NURSING HOME SETTING

    May 1, 2007, 00:00

  • PCV25 THE ECONOMIC AND HEALTH CONSEQUENCES IN MEXICO OF MANAGING HYPERTENSION AND HYPERCHOLESTEROLEMIA WITH A SINGLE PILL THERAPY

    May 1, 2007, 00:00

  • PCASE3 USING OUTCOMES RESEARCH TO SUPPORT ANITBIOTIC SELECTION

    May 1, 2007, 00:00

  • MD4 MEDICAID PREFERRED DRUG LISTS' COSTS TO PHYSICIANS

    May 1, 2007, 00:00

  • PMH3 ANTIDEPRESSANT PROPHYLAXIS FOR POST-STROKE DEPRESSION-A META-ANALYSIS

    May 1, 2007, 00:00

  • PDB3 A RETROSPECTIVE EVALUATION OF HBA1C GOAL ATTAINMENT AMONG VARIOUS DIABETES TREATMENT REGIMENS IN A MANAGED CARE POPULATION

    May 1, 2007, 00:00

  • PUK7 GENERIC SUBSTITUTION OF TACROLIMUS AFTER RENAL TRANSPLANTATION-A DECISION-MAKING MODEL TO WEIGH RISKS AND BENEFITS

    May 1, 2007, 00:00

  • PIN19 COST-EFFECTIVENESS OF GARGLING FOR PREVENTION OF UPPER RESPIRATORY TRACT INFECTIONS

    May 1, 2007, 00:00

  • PCN33 ANALYSIS OF DRUG REQUIREMENT FOR TREATMENT ADVANCED HODGKIN'S DISEASE

    May 1, 2007, 00:00

  • PHP47 DETERMINING ANTIBIOTIC USE IN INDIA

    May 1, 2007, 00:00

  • CASE 2 COST CONTROL FOR MENTAL HEALTH

    May 1, 2007, 00:00

  • PMH2 DIVALPROEX SODIUM VERSUS VALPROIC ACID- DRUG UTILIZATION PATTERNS, PERSISTENCE RATES, AND PREDICTORS OF HOSPITALIZATION AMONG VA PATIENTS DIAGNOSED WITH BIPOLAR DISORDER

    May 1, 2007, 00:00

  • PCN20 COST-OF-ILLNESS- ECONOMIC EVALUATION OF PALLIATIVE 153SM-LEXIDRONAM RADIONUCLIDE TREATMENT IN PATIENTS WITH BONE PAIN SECONDARY TO METASTATIC PROSTATE CANCER

    May 1, 2007, 00:00

  • PIN29 DRUG PRICE, UTILIZATION AND SPENDING FOR ANTIRETROVIRAL MEDICATIONS IN U.S. MEDICAID PROGRAMS FROM 1991 TO 2005

    May 1, 2007, 00:00

  • PHP6 CHARACTERISTICS OF PATIENTS RECEIVING PHARMACEUTICAL SAMPLES AND ASSOCIATION BETWEEN SAMPLE USE AND OUT-OF-POCKET PRESCRIPTION COSTS

    May 1, 2007, 00:00

  • PUK8 COST EFFECTIVENESS OF ICODEXTRINE-BASED SOLUTIONS IN END STAGE RENAL DISEASE PATIENTS UNDERGOING PERITONEAL DIALYSIS THERAPY

    May 1, 2007, 00:00

  • PCN17 MEDICAL COST CONSIDERATIONS OF FIXED DOSING REGIMENS OF ERYTHROPOIETIC AGENTS IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA

    May 1, 2007, 00:00

  • PAA16 PREDICTORS OF THE PRESCRIBING OF ASTHMA PHARMACOTHERAPY IN THE AMBULATORY PATIENT POPULATION OF THE UNITED STATES

    May 1, 2007, 00:00

  • PCN30 A COST—UTILITY ANALYSIS MODEL FOR THE SECOND LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN MEXICO

    May 1, 2007, 00:00

  • PCN7 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING

    May 1, 2007, 00:00

  • PAA2 EXACERBATION RATES FOR SINGLE VS. DUAL CONTROLLER THERAPY FOR MILD-PERSISTENT ASTHMA

    May 1, 2007, 00:00

  • PCASE7 INCLUDING A PHARMACOECONOMIC MODEL IN THE FORMULARY REVIEW PROCESS OF NEW

    May 1, 2007, 00:00

  • PMH42 IMPACT OF ALTERNATIVE CENSORING SPECIFICATIONS ON TIME-TO-EVENT ANALYSES COMPARING ALTERNATIVE MEDICATIONS

    May 1, 2007, 00:00

  • PST7 DOES ADMINISTRATION MODE AFFECT ITEM HIERARCHY IN STROKE SPECIFIC QUALITY OF LIFE MEASURE, STROKE IMPACT SCALE?—TELEPHONE AND MAIL ADMINISTRATION METHODS

    May 1, 2007, 00:00

  • PHM5 RESTROSPECTIVE STUDY OF OUTCOMES AND COSTS IN SICKLE CELL DISEASE (SCD) PATIENTS IN US

    May 1, 2007, 00:00

  • CS2 OUTCOMES ASSOCIATED WITH THE USE OF THIAZOLIDINEDIONES AMONG MEDICARE BENEFICIARIES WITH TYPE II DIABETES—AN INSTRUMENTAL VARIABLE APPROACH

    May 1, 2007, 00:00

  • PMH26 ACCESS TO ILLICT DRUGS- POLICY IMPLICATIONS FROM THE 2003 NATIONAL SURVEY

    May 1, 2007, 00:00

  • PCN56 RELATIONSHIP BETWEEN FUNCTIONAL STATUS AND SELF RATED HEALTH IN PATIENTS WITH PROSTATE CANCER- DATA FROM CAPSURE

    May 1, 2007, 00:00

  • PCN15 COST-EFFECTIVENESS OF NEW TARGETED THERAPY SUNITINIB MALATE AS SECOND LINE TREATMENT IN METASTATIC RENAL CELL CARCINOMA IN ARGENTINA

    May 1, 2007, 00:00

  • PIN5 CLINICAL AND ECONOMIC OUTCOMES OF VANCOMYCIN FOR GRAM-POSITIVE INFECTIONS IN AN ERA OF INCREASING RESISTANCE-A SYSTEMATIC REVIEW

    May 1, 2007, 00:00

  • PAA7 PHARMACOECONOMIC OUTCOMES OF LEVALBUTEROL AND RACEMIC ALBUTEROL IN HOSPITALIZED PATIENTS REQUIRING NEBULIZATION THERAPY (POLARIS)

    May 1, 2007, 00:00

  • PCV2 CLINICAL EXPERIENCE IN DYSLIPIDEMIC PATIENTS TREATED EITHER WITH ROSUVASTATIN 10 MG/DAY OR EZETIMIBE/SIMVASTATIN 10/20 MG/DAY IN MEXICO CITY. A RETROSPECTIVE ANALYSIS

    May 1, 2007, 00:00

  • PCV47 BURDEN OF ILLNESS AMONG PATIENTS AT HIGH RISK FOR MAJOR CARDIOVASCULAR EVENTS

    May 1, 2007, 00:00

  • PGI14 ONE WEEK VERSUS DAILY RECALL OF SYMPTOMS OF INFANT GERD- DOES IT MAKE A DIFFERENCE?

    May 1, 2007, 00:00

  • IN4 ECONOMIC EVALUATION OF INFLUENZA PANDEMIC MITIGATION STRATEGIES IN THE US USING A STOCHASTIC MICROSIMULATION INFLUENZA MODEL

    May 1, 2007, 00:00

  • PMH8 FORECASTING U.S. MEDICAID PROGRAM EXPENDITURE ON ANTIDEPRESSANT DRUGS

    May 1, 2007, 00:00

  • PCV32 IMPACT OF DEPRESSION ON HEALTH STATUS AND HEALTH CARE UTILIZATION IN PATIENTS WITH HYPERTENSION- RESULTS FROM THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS 2002-2003)

    May 1, 2007, 00:00

  • PMC19 HOW GOOD IS GOOD ENOUGH? INTERNAL VALIDITY OF STATED PREFERENCES FOR DRUG THERAPIES

    May 1, 2007, 00:00

  • PDB22 INFLUENCE OF HEMOGLOBIN A1C TEST RESULT ON DECISION TO INITIATE INSULIN SUPPLEMENTATION IN TYPE 2 DIABETES

    May 1, 2007, 00:00

  • AR3 CAUSES AND EFFECTS OF SCENARIO REJECTION- STATED PREFERENCES FOR RHEUMATOID ARTHRITIS TREATMENTS

    May 1, 2007, 00:00

  • Estimating the Rate of Accumulating Drug Resistance Mutations in the HIV Genome

    May 1, 2007, 00:00

  • PMC14 PREDICTORS OF SELF-RATED HEALTH STATUS AMONG GENERAL POPULATION IN THE UNITED STATES USING THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

    May 1, 2007, 00:00

  • PPN4 ECONOMICS OF MORPHINE EQUIVALENT DAILY DOSES (MEDD)

    May 1, 2007, 00:00

  • PHP32 THE STATE OF HEALTH STATUS MEASUREMENT IN LATIN AMERICA

    May 1, 2007, 00:00

  • RS2 INCREMENTAL COSTS ASSOCIATED WITH ANTIBIOTICS PRESCRIBED FOR COMMUNITY ACQUIRED PNEUMONIA

    May 1, 2007, 00:00

  • WH3 REDUCED WORK LIMITATION WITH IMPROVEMENT IN MOOD, SLEEP AND VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL WOMEN

    May 1, 2007, 00:00

  • PUK2 OUTCOMES AND COSTS ASSOCIATED WITH IMMUNOSUPPRESSION COMPLIANCE

    May 1, 2007, 00:00

  • PEN1 ESTIMATING THE QALY BENEFITS OF TREATMENT FOR GROWTH HORMONE DEFICIENCY (GHD) IN ADULT PATIENTS-A PRECURSOR TO COST-EFFECTIVENESS ANALYSIS

    May 1, 2007, 00:00

  • PSU3 SAVINGS OF THE USE OF RHBMP-2 IN OPEN TIBIA FRACTURES FOR EUROPEAN HEALTH CARE SYSTEMS FROM A PAYER AND SOCIETAL PERSPECTIVE

    May 1, 2007, 00:00

  • PHP20 IMPACT OF POLYPHARMACY MEDICATION THERAPY MANAGEMENT PROGRAM (MTMP) ON DRUG EXPENDITURES IN MEDICARE PART D POPULATION

    May 1, 2007, 00:00

  • PMC1 FORECASTING WITH TIME SERIES MODELS TO EXAMINE THE AVAILABILITY OF INPATIENT BEDS

    May 1, 2007, 00:00

  • PCASE6 CLINICAL OUTCOMES ASSESSMENT IN BEHAVIORAL HEALTH CARE- SEARCHING FOR PRACTICAL SOLUTIONS

    May 1, 2007, 00:00

  • PIN11 COST-EFFECTIVENESS OF SUBSTITUTING LAMIVUDINE (LVD) WITH ENTECAVIR (ETV) IN CHRONIC HEPATITIS B (CHB) PATIENTS IN THE PUBLIC SECTOR OF HONG KONG

    May 1, 2007, 00:00

  • PMH33 PROFILING UTILIZATION PATTERNS OF ANTIPSYCHOTICS AMONG PATIENTS WITH BIPOLAR DISORDER-A CLAIMS DATA ANALYSIS

    May 1, 2007, 00:00

  • PCV20 A COST-EFFECTIVENESS STUDY COMPARING IVABRADINE WITH STANDARD CARE IN STABLE ANGINA PECTORIS IN THE NETHERLANDS

    May 1, 2007, 00:00

  • PCN18 BURDEN OF ILLNESS ANALYSIS OF MALIGNANT METASTATIC MELANOMA IN THE UNITED STATES

    May 1, 2007, 00:00

  • PPN16 PRESCRIBING OF FENTANYL PATCHES TO NON-OPIOID TOLERANT PATIENTS IN THE MILITARY HEALTH SYSTEM (MHS)

    May 1, 2007, 00:00

  • PDB17 DETERMINATION OF HEALTH CARE COSTS INCURRED BY SWEDISH PATIENTS WITH TYPE 2 DIABETES

    May 1, 2007, 00:00

  • PAR16 A COMPARISON OF SWITCHING PATTERNS AMONG ANTITUMOR NECROSIS FACTORS (ANTI-TNFS) IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    May 1, 2007, 00:00

  • PCASE1 APPLICATION OF PHARMACOECONOMICS TO DOD'S ANTILIPIDEMIC-1 UNIFORM FORMULARY DECISION

    May 1, 2007, 00:00

  • PCV31 COST-EFFECTIVENESS OF ACHIEVING ADDITIONAL LIPID TARGETS WHEN SUBSTITUTING FENOFIBRATE 145 MG FOR STANDARD FENOFIBRATE THERAPY

    May 1, 2007, 00:00

  • PMH23 ECONOMIC EVALUATION OF LONG ACTING TREATMENTS FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN THE MILITARY HEALTH SYSTEM

    May 1, 2007, 00:00

  • PDB25 HEALTH STATUS AND QUALITY OF LIFE IN TYPE 2 DIABETES MELLITUS- RELATIONSHIPS IN A CROSS-SECTIONAL STUDY

    May 1, 2007, 00:00

  • PIH10 BURDEN OF PREMENSTRUAL DYSPHORIC DISORDER ON HEALTH-RELATED QUALITY OF LIFE

    May 1, 2007, 00:00

  • PCN40 PATTERNS OF TREATMENT OF NON SMALL CELL LUNG CANCER (NSCLC) IN COMMUNITY PRACTICE

    May 1, 2007, 00:00

  • PCN2 ASSESSING THE NET HEALTH OUTCOMES OF A 4D ELECTROMAGNETIC TUMOR TRACKING SYSTEM DURING RADIOTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER-A HEALTH TECHNOLOGY ASSESSMENT OF THE CALYPSO® 4D LOCALIZATION SYSTEM WITH BEACON® TRANSPONDER ...

    May 1, 2007, 00:00

  • PCV44 EFFECTS OF MEDICAID ACCESS RESTRICTIONS ON STATIN UTILISATION FOR PATIENTS TREATED BY PHYSICIANS PRACTISING IN POOR AND MINORITY NEIGHBORHOODS

    May 1, 2007, 00:00

  • PCN1 COLONIC STENTING VERSUS SURGERY FOR MALIGNANT LARGE BOWEL OBSTRUCTION- COMPARATIVE ASSESSMENT OF OUTCOMES AND COST

    May 1, 2007, 00:00

  • PCV13 METABOLIC SYNDROME PREVALENCE IN A HYPERTENSIVE POPULATION

    May 1, 2007, 00:00

  • PMH7 SUICIDALITY AND ANTIDEPRESSANTS USE IN CHILDREN AND ADOLESCENTS

    May 1, 2007, 00:00

  • PCN3 CORRELATION BETWEEN TIME TO PROGRESSION AND OVERALL SURVIVAL IN PATIENTS WITH METASTATIC BREAST CANCER

    May 1, 2007, 00:00

  • PCN38 WITHIN COUNTRY DIFFERENCES IN MAMMOGRAPHY COVERAGE OF THE HUNGARIAN NATIONWIDE ORGANIZED BREAST CANCER SCREENING PROGRAMME

    May 1, 2007, 00:00

  • MC4 TIME HORIZON BIAS IN ECONOMIC EVALUATIONS

    May 1, 2007, 00:00

  • PDB11 THE COST-EFFECTIVENESS OF VACUUM ASSISTED CLOSURE® (V.A.C.) THERAPY FOR THE TREATMENT OF DIABETIC FOOT WOUNDS

    May 1, 2007, 00:00

  • PEY13 ADJUNCTIVE THERAPY USE BY GLAUCOMA PATIENTS ON ORAL ANTIHYPERTENSIVES

    May 1, 2007, 00:00

  • PIN3 TREATMENT FAILURE, COMPLICATIONS AND COSTS OF LEVOFLOXACIN VS.AMOXICILLIN/CLAVULANATE ANTIBIOTIC THERAPY IN OUTPATIENT COMMUNITY ACQUIRED PNEUMONIA (CAP)

    May 1, 2007, 00:00

  • PCV53 PROFILES OF INITIAL DRUG THERAPIES AMONG NEWLY DIAGNOSED HYPERTENSIVE PATIENTS WITH NO COMPELLING INDICATIONS

    May 1, 2007, 00:00

  • PMC24 PSYCHOMETRIC EVALUATION OF INSTRUMENTS USED TO MEASURE PATIENT SATISFACTION WITH PHARMACIST SERVICES

    May 1, 2007, 00:00

  • Substantial Treatment Overuse in the United States?—Response to Grandjour

    May 1, 2007, 00:00

  • CN4 PSYCHOMETRIC VALIDATION OF A PATIENT SYMPTOM ASSESSMENT-LUNG CANCER (PSALC) INSTRUMENT FOR SMALL CELL LUNG CANCER (SCLC)

    May 1, 2007, 00:00

  • PGI18 GASTROESOPHAGEAL REFLUX DISEASE AND HEALTHRELATED QUALITY OF LIFE IN THE GENERAL POPULATION OF SHANGHAI, CHINA

    May 1, 2007, 00:00

  • PST6 GENERIC AND DISEASE-SPECIFIC HEALTH RELATED QUALITY OF LIFE (HRQOL) IN STROKE SURVIVORS

    May 1, 2007, 00:00

  • The Relationship between Influenza Vaccination and Outpatient Visits for Upper Respiratory Infection by the Elderly in Taiwan

    Mar 1, 2007, 00:00

  • The Cost-Effectiveness of Expanding Newborn Screening for up to 21 Inherited Metabolic Disorders Using Tandem Mass Spectrometry- Results from a Decision-Analytic Model

    Mar 1, 2007, 00:00

  • Economic Burden of Osteoporosis-Related Fractures in Medicaid

    Mar 1, 2007, 00:00

  • Reduced Mortality Rates after Intensive Statin Therapy in Managed-Care Patients

    Mar 1, 2007, 00:00

  • Comment on “Where's the Value in Health Care?”

    Mar 1, 2007, 00:00

  • The Cost-Effectiveness of Influenza Vaccination for People Aged 50 to 64 Years- An International Model

    Mar 1, 2007, 00:00

  • Effect of Second-Generation Antidepressants on Mania- and Depression-Related Visits in Adults with Bipolar Disorder- A Retrospective Study

    Mar 1, 2007, 00:00

  • The Author's Reply to Comment on “Where's the Value in Health Care?”

    Mar 1, 2007, 00:00

  • The Impact of Atrial Fibrillation on the Cost of Stroke- The Berlin Acute Stroke Study

    Mar 1, 2007, 00:00

  • Health-Related Quality of Life Measured with EQ-5D in Patients Treated for Depression in Primary Care

    Mar 1, 2007, 00:00

  • Cost-Effectiveness Analysis of a Quality-Controlled Mammography Screening Program from the Swiss Statutory Health-Care Perspective- Quantitative Assessment of the Most Influential Factors

    Jan 1, 2007, 00:00

  • Economic Evaluation of Palliative Management versus Peritoneal Dialysis and Hemodialysis for End-Stage Renal Disease- Evidence for Coverage Decisions in Thailand

    Jan 1, 2007, 00:00

  • Cardioverter Defibrillators in Primary Prevention of Sudden Cardiac Death- A Cost or an Investment?

    Jan 1, 2007, 00:00

  • A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases

    Jan 1, 2007, 00:00

  • Is It Time for Managed Care Organizations to Cover Weight Reduction?

    Jan 1, 2007, 00:00

  • The Effect of Disease, Functional Status, and Relapses on the Utility of People with Multiple Sclerosis in the UK

    Jan 1, 2007, 00:00

  • Using EQ-5D to Derive General Population-based Utilities for the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA)

    Jan 1, 2007, 00:00

  • Assessment of Cardiometabolic Risk Factors in a National Primary Care Electronic Health Record Database

    Jan 1, 2007, 00:00

  • Economic Burden and Risk of Cardiovascular Disease and Diabetes in Patients with Different Cardiometabolic Risk Profiles

    Jan 1, 2007, 00:00

  • Metabolic Syndrome and Employer Sponsored Medical Benefits- An Actuarial Analysis

    Jan 1, 2007, 00:00

  • Cost-Effectiveness of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy

    Jan 1, 2007, 00:00

  • Predicting the Prevalence of Cardiometabolic Risk Factors When Clinical Data Are Limited

    Jan 1, 2007, 00:00

  • The Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease

    Jan 1, 2007, 00:00

  • Special Issue- Exploring Cardiometabolic Complications of Obesity and Related Risk Factors- Prevalence and Economic Consequences

    Jan 1, 2007, 00:00

  • Foreword- Exploring Cardiometabolic Complications of Obesity and Related Risk Factors- Prevalence and Economic Consequences

    Jan 1, 2007, 00:00

  • Age-Specific Impact of Obesity on Prevalence and Costs of Diabetes and Dyslipidemia

    Jan 1, 2007, 00:00

  • Cost-Benefit Analysis of Preventing Sudden Cardiac Deaths with an Implantable Cardioverter Defibrillator versus Amiodarone

    Jan 1, 2007, 00:00

  • Simple Demographic Model to Predict Multiple Cardiometabolic Risk Factors in Two Well-Known Observational Cohorts

    Jan 1, 2007, 00:00

  • Cardiovascular Risk Factor Clusters and Employment in the United States

    Jan 1, 2007, 00:00

  • PDB29 COMPARING THE DEVELOPMENT OF A GERMAN DIABETES POPULATION WITH RESPECT TO LONGTERM OUTCOMES USING DATA FROM THE DETECT STUDY AND THE EAGLE DIABETES SIMULATION MODEL

    Nov 1, 2006, 00:00

  • PSU3 DEMOGRAPHIC PREDICTORS OF RESOURCE UTILIZATION AND COSTS OF SOLID ORGAN TRANSPLANTATION IN BRITISH COLUMBIA, CANADA

    Nov 1, 2006, 00:00

  • PMH19 IMPACT OF REMISSION IN MAJOR DEPRESSIVE DISORDER ON ECONOMIC BURDEN OF ILLNESS IN SWEDEN

    Nov 1, 2006, 00:00

  • PUK20 PATIENTS UNDER 65 YEARS OF AGE ON RENAL TRANSPLANT WAITING LISTS SHOW A WORSE PERCEIVED STATE OF HEALTH THAN OLDER ONES

    Nov 1, 2006, 00:00

  • PDB22 EVALUATING THE LONG-TERM HEALTH OUTCOMES AND ECONOMICS OF INITIATING BIPHASIC ANALOG INSULIN COMPARED TO OPTIMIZED ORAL THERAPY ALONE

    Nov 1, 2006, 00:00

  • PCV3 DO WE FOLLOW THE GUIDELINES ON PREVENTION OF CARDIOVASCULAR DISEASE IN OUT-PATIENT CARE?

    Nov 1, 2006, 00:00

  • OA2 SCREENING FOR PATIENTS AT RISK FOR OSTEOPOROSIS BASED ON A RISK-QUESTIONNAIRE IN A GERMAN SETTING OF COMMUNITY PHARMACIES

    Nov 1, 2006, 00:00

  • PHP2 RACIAL/ETHNIC DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AND OUT-OF-POCKET COSTS

    Nov 1, 2006, 00:00

  • PCN67 PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING WITH 5HT3 RECEPTOR ANTAGONISTS AND HEALTH RELATED QOL

    Nov 1, 2006, 00:00

  • PCV9 NON-PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS LEADS TO INCREASED RISK OF HOSPITALIZATIONS FOR ACUTE MYOCARDIAL INFARCTION OR STROKE

    Nov 1, 2006, 00:00

  • PCV14 ASCOT-LIKE PATIENT PREVALENCE AMONG THE HYPERTENSIVES IN SPAIN

    Nov 1, 2006, 00:00

  • MC2 15DS-A NEW DYNAMIC QUALITY OF LIFE TOOL WITH INCREASED SENSITIVITY AND IMPROVED COMPOSITE STRUCTURE FOR RECALL BIAS AND RESPONSE SIFT ADJUSTMENTS

    Nov 1, 2006, 00:00

  • PCV15 ANALYSIS OF PRESCRIBING PATTERNS OF ANTIHYPERTENSIVE AGENTS (AA) BEFORE AND AFTER PUBLICATION OF THE ANTIHYPERTENSIVE AND LIPIDLOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT)

    Nov 1, 2006, 00:00

  • PMC13 EMPIRICAL RESEARCH FOR WILLINGNESSTO PAYFOR ONE QALY GAIN

    Nov 1, 2006, 00:00

  • PEY23 VISION WITH RESTOR® VERSUS MONOFOCAL INTRAOCULAR LENSES (IOL) AFTER CATARACT SURGERY- RESULTS OF A POOLED ANALYSIS

    Nov 1, 2006, 00:00

  • PDB41 EFFECT OF COMPLICATIONS ON HEALTH RELATED QUALITY OF LIFE IN HUNGARIAN INSULIN TREATED DIABETIC PATINETS

    Nov 1, 2006, 00:00

  • PIN32 VALIDATION OF THE PATIENTS' ATTITUDES AND PERCEPTIONS TOWARDS HAART QUESTIONNAIRE

    Nov 1, 2006, 00:00

  • PEY16 COST-UTILITY ANALYSIS FOR PEGAPTANIB IN AGE-RELATED MACULAR DEGENERATION IN THE UK- THE IMPACT OF DEMOGRAPHIC AND DISEASE CHARACTERISTICS

    Nov 1, 2006, 00:00

  • PIN23 INDICATOR OF ANTIBIOTIC USE IN PUBLIC PHARMACY CHAIN BELGRADE

    Nov 1, 2006, 00:00

  • POS9 COMPARISON OF THE BURDEN OF ILLNESS OF DISPLACED AND UNDISPLACED FEMORAL NECK FRACTURE AFTER REDUCTION INTERNAL FIXATION

    Nov 1, 2006, 00:00

  • PCV17 PROJECTED IMPACT ON CORONARY HEART DISEASE OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) TO STATIN TREATMENT IN EUROPEAN PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2006, 00:00

  • PMC9 A REVIEW OF FACTORS AFFECTING THERAPEUTIC COMPLIANCE

    Nov 1, 2006, 00:00

  • PCV73 ANALYSIS OF COST AND EFFECTIVENESS DATA USING RANDOM PERMUTATION METHODS

    Nov 1, 2006, 00:00

  • PUK22 COMPARISON OF THE PRO ENDPOINTS FOUND IN LABELING CLAIMES OF URINARY INCONTINENCE DRUGS WITH THOSE RECOMMENDED BY THE CORRESPONDING EMEA NOTE FOR GUIDANCE

    Nov 1, 2006, 00:00

  • PDB42 PATIENT AND PHYSICIAN DRIVERS OF HEALTH-RELATED QUALITY LIFE OF PATIENTS WITH TYPE 2 DIABETES IN PRIMARY CARE IN SPAIN

    Nov 1, 2006, 00:00

  • PEY24 METRIC PROPERTIES OF THE MACDQOL IN FRENCH, GERMAN, ITALIAN, AND AMERICAN POPULATIONS- AN INDIVIDUALISED QOL INSTRUMENT SPECIFIC TO MACULAR DISEASE (MD)

    Nov 1, 2006, 00:00

  • POS16 LONG TERM QUALITY OF LIFE RELATED TO OSTEOPOROTIC FRACTURES; 13–18 MONTHS AFTER FRACTURE

    Nov 1, 2006, 00:00

  • PMH35 REDUCTION IN SUICIDAL IDEATION AND VIOLENT BEHAVIOUR AFTER SIX MONTHS OF TREATMENT WITH LONG ACTING RISPERIDONE IN PATIENTS ENROLLED IN THE ELECTRONIC SCHIZOPHRENIA ADHERENCE TREATMENT REGISTRY (E-STAR)

    Nov 1, 2006, 00:00

  • CN4 COST-EFFECTIVENESS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NONSMALL CELL LUNG CANCER (NSCLC) IN THE UK

    Nov 1, 2006, 00:00

  • PSU2 ECONOMIC EVALUATION COMPARING FROM HOME TO OPERATION AND CONVENTIONAL PROCESS OF LAPAROSCOPIC CHOLECYSTECTOMY- PROSPECTIVE RANDOMIZED CONTROLLED TRIAL

    Nov 1, 2006, 00:00

  • PCN35 BURDEN OF ILLNESS OF RENAL CELL CARCINOMA IN SPAIN

    Nov 1, 2006, 00:00

  • PHM3 HEPARIN-RELATED THROMBOCYTOPENIA ASSOCIATED WITH MAJOR INCREASE IN HOSPITAL COSTS

    Nov 1, 2006, 00:00

  • PRS7 ESTIMATION OF MORBIDITY, RESOURCE UTILIZATION AND COST IN SUBJECTS TREATED WITH TIOTROPIUM BROMIDE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN A SPANISH POPULATION SETTING

    Nov 1, 2006, 00:00

  • RS3 THE COST-EFFECTIVENESS OF TIOTROPIUM VERSUS IPRATROPIUM IN A US VETERANS POPULATION DIAGNOSED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Nov 1, 2006, 00:00

  • PAA8 A COMPARISON OF CLAIMS RATIO BETWEEN PRIMARY AND SECONDARY DRUGS IN THE MANAGEMENT OF ASTHMA. A CANADIAN ANALYSIS

    Nov 1, 2006, 00:00

  • PIN24 THE USE OF ANTIBIOTICS IN CHILDREN POPULATION IN BELGRADE REGION

    Nov 1, 2006, 00:00

  • PAA9 THE EFFECTS OF GENERIC-ONLY DRUG COVERAGE ON INHALED CORTICOSTEROID EXPENDITURES AND USE

    Nov 1, 2006, 00:00

  • PAA2 EFFECT OF SUBLINGUAL IMMUNOTHERAPY (SLIT) ON DIRECT MEDICAL COSTS FOR PATIENTS WITH ALLERGIC RHINITIS AND ASTHMA- RESULTS FROM THE SIMAP DATABASE STUDY

    Nov 1, 2006, 00:00

  • PUK6 COST-EFFECTIVENESS OF TREATMENT WITH EPOIETIN ALPHA FOR PATIENTS WITH ANAEMIA DUE TO RENAL FAILURE—THE CASE OF SWEDEN

    Nov 1, 2006, 00:00

  • PEY27 DEVELOPMENT OF A QUESTIONNAIRE ASSESSING PATIENT SATISFACTION WITH EYE DROPS IN OCULAR HYPERTENSION AND GLAUCOMA

    Nov 1, 2006, 00:00

  • PCN68 QUALITY OF LIFE OF PATIENTS RECEIVING ADJUVANT CHEMOTHERAPIES FOR BREAST CANCER IN JAPAN

    Nov 1, 2006, 00:00

  • PMH16 COST EFFECTIVENESS MODEL COMPARING FAST DISSOLVING OLANZAPINE AND CONVENTIONAL OLANZAPINE TABLETS IN THE TREATMENT OF SCHIZOPHRENIA

    Nov 1, 2006, 00:00

  • PND4 PREGABALIN VS GABAPENTIN IN THE TREATMENT OF NEUROPATHIC PAIN IN ITALY- A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2006, 00:00

  • CV5 PHARMACOECONOMIC EVALUATION OF SIMVASTATIN VERSUS “NO TREATMENT” IN PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE (CHD) IN POLAND

    Nov 1, 2006, 00:00

  • HP1 CRITICAL APPRAISAL OF ECONOMIC EVALUATIONS OF CHOLESTEROL LOWERING DRUGS-A SYSTEMATIC REVIEW

    Nov 1, 2006, 00:00

  • IH3 FEASIBILITY AND PRIMARY VALIDITY OF A GERMAN EQ-5D CHILDREN'S VERSION

    Nov 1, 2006, 00:00

  • PMC14 MEASURING PATIENT-REPORTED SIDE EFFECTS OF DRUGS- ITS IMPORTANCE AND METHODOLOGICAL CHALLENGES

    Nov 1, 2006, 00:00

  • CN1 TREATMENTS FOR METASTATIC MELANOMA- SYNTHESIS OF EVIDENCE FROM RANDOMIZED TRIALS

    Nov 1, 2006, 00:00

  • PIN30 PSYCHOMETRIC VALIDATION OF THE ACTIVITY IMPAIRMENT ASSESSMENT (AIA) QUESTIONNAIRE IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS

    Nov 1, 2006, 00:00

  • PMH40 ASSESSING SELECTION BIAS ON TREATMENT EFFECTS IN OBSERVATIONAL STUDIES WITH REPEATED OUTCOME MEASURES- REGRESSION, PROPENSITY SCORING, FIXEDEFFECTS MODELS, AND BAYESIAN ESTIMATION METHODS

    Nov 1, 2006, 00:00

  • PSK2 MEDICATION ADHERENCE AND HEALTH CARE COSTS ASSOCIATED WITH BIOLOGICS IN MEDICAID-ENROLLED PATIENTS WITH PSORIASIS

    Nov 1, 2006, 00:00

  • PIN1 CLINICAL AND ECONOMIC IMPACT OF INTRODUCING A QUADRIVALENT (6, 11, 16, 18) HUMAN PAPILLOMAVIRUS VACCINE IN SWITZERLAND

    Nov 1, 2006, 00:00

  • PND8 COST-EFFECTIVENESS OF TREATING RESTLESS LEGS PATIENTS WITH PRAMIPEXOLE COMPARED TO NO TREATMENT IN SWEDEN

    Nov 1, 2006, 00:00

  • PHM7 DIRECT COST OF BETA THALASSEMIA MAJOR- RESUTS FROM THE ITHACA STUDY

    Nov 1, 2006, 00:00

  • PMH45 CROSS-SECTIONAL EVALUATION OF HEALTH STATE UTILITY IN SWEDISH OUTPATIENTS SUFFERING FROM MAJOR DEPRESSIVE DISORDER

    Nov 1, 2006, 00:00

  • PCN50 BOWEL CANCER SCREENING. BALANCING COSTEFFECTIVENESS AND AFFORDABILITY

    Nov 1, 2006, 00:00

  • PST3 RESOURCE UTILIZATION AND COSTS OF STROKES IN A THIRD LEVEL HOSPITAL IN MÉXICO

    Nov 1, 2006, 00:00

  • PHP33 OCCUPATIONAL INJURIES- USE AND COST OF EMERGENCY DEPARTMENT FOR TREATMENT OF ACCIDENTAL HYPODERMIC NEEDLE PUNCTURES

    Nov 1, 2006, 00:00

  • PAR10 THE COST-UTILITY OF ADALIMUMAB (HUMIRA®) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN DENMARK

    Nov 1, 2006, 00:00

  • PAR8 TRENDS IN PRESCRIPTION CLAIMS FOLLOWING THE WITHDRAWAL OF ROFECOXIB FROM THE CANADIAN MARKET

    Nov 1, 2006, 00:00

  • PAR6 COST-UTILITY ANALYSIS OF RITUXIMAB AS A NEW THERAPEUTIC OPTION FOR RHEUMATOID ARTHRITIS PATIENTS IN CANADA

    Nov 1, 2006, 00:00

  • POB3 BURDEN OF ILLNESS OF ABDOMINAL OBESITY- A RETROSPECTIVE CHART REVIEW

    Nov 1, 2006, 00:00

  • PCV85 COMPLIANCE AND PERSISTENCE OF FIXED DOSE VERSUS FREE DOSE COMBINATION THERAPY WITH VALSARTAN AND HCTZ FOR PATIENTS WITH HYPERTENSION

    Nov 1, 2006, 00:00

  • PEY2 EFFECTIVENESS OF TRAVOPROST VERSUS DORZOLAMIDE + TIMOLOL FIXED COMBINATION IN FIRST LINE TREATMENT OF GLAUCOMA-ANALYZED FROM THE UK GENERAL PRACTITIONER RESEARCH DATABASE

    Nov 1, 2006, 00:00

  • PCN39 COST-UTILITY ANALYSIS IN A FRENCH SETTING OF ADJUVANT THERAPY WITH HERCEPTIN IN PATIENTS WITH HER-2 POSITIVE BREAST CANCER

    Nov 1, 2006, 00:00

  • PCN31 A COST MINIMISATION ANALYSIS OF NAVELBINE-CISPLATIN VERSUS GEMCITABINE-CISPLATIN IN ADVANCED NONSMALL CELL LUNG CANCER IN POLAND

    Nov 1, 2006, 00:00

  • PGI12 GASTROINTESTINAL COMPLICATIONS INDUCED BY NONSTERIODAL ANTI-INFLAMMATORY DRUGS (NSAID)- EPIDEMIOLOGICAL EXTRAPOLATION FOR EUROPE AND ECONOMIC CONSIDERATIONS

    Nov 1, 2006, 00:00

  • PDB12 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION VERSUS MULTIPLE DAILY INJECTION OF INSULIN IN PATIENTS WITH TYPE 1 DIABETES-A LONG-TERM HEALTH ECONOMIC ANALYSIS IN THE NORWEGIAN AND SWEDISH SETTINGS

    Nov 1, 2006, 00:00

  • PHP28 PILOT STUDY OF THE IMPACT OF NEW PRICING SCHEMA ON DRUG PRICES IN REPUBLIC SERBIA

    Nov 1, 2006, 00:00

  • PND5 TREATMENT OF EARLY PARKINSONIAN PATIENTS WITH RASAGILINE OR ROPINIROLE. WHAT IS THE MOST COSTEFFECTIVE TREATMENT STRATEGY IN FINLAND?

    Nov 1, 2006, 00:00

  • SZ1 EFFECTIVENESS AND COSTS OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA IN ROUTINE CARE

    Nov 1, 2006, 00:00

  • PAR2 ZOLEDRONIC ACID IN THE LONG-TERM MANAGEMENT OF PAGET'S DISEASE OF THE BONE IN GERMANY-A COSTSAVING APPROACH?

    Nov 1, 2006, 00:00

  • PHP19 DRUG PRICE INDICES 1980–2005 IN FINLAND

    Nov 1, 2006, 00:00

  • PGI6 THE USE OF BUDGET IMPACT MODELLING TO ASSESS THE ECONOMIC CONSEQUENCE OF CHANGING THE PRESCRIPTION PATTERN OF PROTON PUMP INHIBITORS (PPI) IN SWEDEN

    Nov 1, 2006, 00:00

  • PCN22 COST-EFFECTIVENESS (CE) OF THE PREVENTION OF ORAL MUCOSITIS (OM) WITH KEPIVANCE® (PALIFERMIN) IN PATIENTS UNDERGOING MYELOABLATIVE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN SPAIN

    Nov 1, 2006, 00:00

  • PCN23 ADDING RITUXIMAB TO STANDARD CHEMOTHERAPY IS COST NEUTRAL AND CLINICALLY SUPERIOR IN ADVANCED STAGE NON-HODGKIN'S LYMPHOMA (NHL)

    Nov 1, 2006, 00:00

  • PCV78 TOWARDS A MODELLED ECONOMIC EVALUATION TO IDENTIFY THE OPTIMAL POPULATION FOR SCREENING OF CORONARY ARTERY DISEASE

    Nov 1, 2006, 00:00

  • PCN47 COUNTY LEVEL INEQUALITIES IN THE ATTENDANCE OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME

    Nov 1, 2006, 00:00

  • PCV44 COMORBIDITIES, COSTS AND THERAPEUTIC GOALS ACHIEVED IN THE SECONDARY PREVENTION OF THE PRIMARY HEALTH CARE

    Nov 1, 2006, 00:00

  • PRS19 EPIDEMIOLOGICAL STUDY TO INVESTIGATE PATIENTS' VIEWS ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2006, 00:00

  • PHM6 SOCIETAL COSTS OF ALLOGENEIC BLOOD TRANSFUSION IN THE NETHERLANDS

    Nov 1, 2006, 00:00

  • PMC11 EFFECTIVE USE OF ELECTRONIC DATA CAPTURE (EDC) TO IMPROVE THE QUALITY AND EFFICIENCY OF THE ANALYSIS OF PATIENT REPORTED OUTCOMES

    Nov 1, 2006, 00:00

  • PEY18 CHANGES IN MEDICAL AND SURGICAL TREATMENTS OF GLAUCOMA BETWEEN 1997 AND 2003 IN FRANCE

    Nov 1, 2006, 00:00

  • DB1 RATES AND RISKS OF STARTING INSULIN IN DIABETES MELLITUS TYPE-2 PATIENTS

    Nov 1, 2006, 00:00

  • PSM2 COST-UTILITY ANALYSIS FOR SMOKING CESSATION THERAPY IN JAPAN

    Nov 1, 2006, 00:00

  • PAA3 COST OF MANAGING ASTHMA EXACERBATIONS WITH STABLE DOSING OF SALMETEROL/FLUTICASONE COMBINED PRODUCT (SFC) COMPARED WITH ADJUSTABLE MAINTENANCE DOSING (AMD) OF FORMOTEROL/BUDESONIDE COMBINED PRODUCT (FBC) IN POLAND

    Nov 1, 2006, 00:00

  • POS11 EVOLUTION OF THE CONSUMPTION OF BISPHOSPHONATES AND RALOXIFENE FINANCED BY THE SPANISH NATIONAL HEALTH SYSTEM FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

    Nov 1, 2006, 00:00

  • PND11 MODELING LONG-TERM “REAL WORLD” OUTCOMES OF DISEASE-MODIFYING THERAPY IN RELAPSING-REMITTING ONSET MULTIPLE SCLEROSIS

    Nov 1, 2006, 00:00

  • PEY19 PROSTAGLANDIN AGONIST USE WITH AND WITHOUT ADJUNCTIVE THERAPY FOR THE TREATMENT OF GLAUCOMA- A CANADIAN POPULATION BASED ANALYSIS

    Nov 1, 2006, 00:00

  • PCV68 CLOPIDOGREL PATTERNS OF USE IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN 5 EUROPEAN COUNTRIES

    Nov 1, 2006, 00:00

  • PCN36 BURDEN OF CERVICAL CANCER IN POLAND

    Nov 1, 2006, 00:00

  • PCN64 DIFFERENTIAL ITEM FUNCTIONING USING RASCH ANALYSIS

    Nov 1, 2006, 00:00

  • PSK5 COST OF ATOPIC DERMATIS IN ADULTS- THE CODA STUDY

    Nov 1, 2006, 00:00

  • PDB35 COST-EFFECTIVENESS OF INHALED INSULIN IN PATIENTS WITH DIABETES UNCONTROLLED ON THEIR CURRENT THERAPY- THE UK BASE CASE SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)

    Nov 1, 2006, 00:00

  • PDB38 ADHERENCE TO STATIN TREATMENT IN PEOPLE WITH TYPE 1 AND TYPE 2 DIABETES

    Nov 1, 2006, 00:00

  • PSM1 THE HIGH COST OF CIGARETTE SMOKING IN GERMANY IN 2003

    Nov 1, 2006, 00:00

  • GI2 DICLOFENAC-ASSOCIATED ULCER RISK IS REDUCED BY PROTON PUMP INHIBITORS- NESTED CASE CONTROL STUDY

    Nov 1, 2006, 00:00

  • PEY22 MEDICATION ADHERENCE AND HEALTH CARE COSTS WITH INTRODUCTION OF LATANOPROST THERAPY FOR GLAUCOMA IN A MEDICARE MANAGED CARE POPULATION

    Nov 1, 2006, 00:00

  • PMH21 COST-UTILITY ANALYSIS OF ANTIDEPRESSANTS FOR SECOND-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER

    Nov 1, 2006, 00:00

  • PCV39 PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN PATIENTS WITH TYPE II DIABETES A COST-MINIMIZATION ANALYSIS

    Nov 1, 2006, 00:00

  • PHP26 SUPPLY SIDE COST-CONTAINMENT IN GERMANY- WIN SOME, LOSE SOME

    Nov 1, 2006, 00:00

  • PHM14 PATIENT PREFERENCE AND WILLINGNESS-TO-PAY FOR ANTICOAGULANT TREATMENT OPTIONS IN PATIENTS RECEIVING ORAL ANTICOAGULANT TREATMENT (OAT)- A DISCRETE CHOICE EXERCISE

    Nov 1, 2006, 00:00

  • PCN62 UTILITY ELICITATION IN PATIENTS WITH FOLLICULAR LYMPHOMA

    Nov 1, 2006, 00:00

  • PDB23 THE COST-EFFECTIVENESS OF INHALED INSULIN IN SWEDEN

    Nov 1, 2006, 00:00

  • PAR11 ARE THEY MEASURABLE? A STUDY ON ELICITING INDIRECT AND INTANGIBLE COSTS OF KNEE OSTEOARTHRITIS USING HUMAN CAPITAL APPROACH AND WILLINGNESS-TO-PAY IN MULTIETHNIC ASIAN POPULATION IN SINGAPORE

    Nov 1, 2006, 00:00

  • PCN12 COST EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) IN POLAND

    Nov 1, 2006, 00:00

  • PUK11 COST UTILITY ANALYSIS OF ERYTHROPOIETIN THERAPY IN THE MINISTRY OF HEALTH DIALYSIS PROGRAMME

    Nov 1, 2006, 00:00

  • PHP12 WASTAGE OF MEDICINES IN PORTUGAL

    Nov 1, 2006, 00:00

  • POS8 THE SOCIETAL BURDEN OF OSTEOPOROSIS

    Nov 1, 2006, 00:00

  • PCV33 COST-EFFECTIVENESS MODEL TO EVALUATE MANAGED VENTRICULAR PACING (MVP) IMPLANTED IN A SPANISH AMBULATORY SURGERY PROGRAM

    Nov 1, 2006, 00:00

  • PEY15 LATANOPROST VERSUS TIMOLOL MONOTHERAPY FOR THE TREATMENT OF GLAUCOMA-A COST-EFFECTIVNESS ANALYSIS IN SCANDINAVIA AND THE UK USING A DECISION-ANALYTIC HEALTH ECONOMIC MODEL

    Nov 1, 2006, 00:00

  • RS2 TREATMENT WITH INHALED CORTICOSTEROIDS IN ASTHMA TOO OFTEN DISCONTINUED

    Nov 1, 2006, 00:00

  • PCV41 A COST CONSEQUENCE ANALYSIS OF THE IMPACT OF JBS 2 ON PATIENTS ELIGIBLE FOR STATIN TREATMENT IN SCOTLAND

    Nov 1, 2006, 00:00

  • PRS18 MEASURING DISEASE-SPECIFIC UTILITIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE HEALTH- AND EXACERBATION PROFILES

    Nov 1, 2006, 00:00

  • PHP40 COST-EFFECTIVENESS STUDY OF ADJUSTED CLINICAL GROUPS TO ASSESS THE ABILITY OF SPANISH PRIMARY CARE TEAMS TO BRING ISSUES TO RESOLUTION

    Nov 1, 2006, 00:00

  • PSK9 QUALITY OF LIFE OF ADULT PATIENTS WITH ATOPIC DERMATITIS- THE CODA STUDY

    Nov 1, 2006, 00:00

  • PCV56 ESTIMATION OF THE PRESENCE OF CARDIOVASCULAR EVENTS AND DIRECT COSTS ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN AN AMBULATORY SETTING

    Nov 1, 2006, 00:00

  • POS4 COMPARING THE COST-EFFECTIVENESS OF RHBMP-2 IN THE TREATMENT OF OPEN TIBIA FRACTURES IN GERMANY, FRANCE, AND UK

    Nov 1, 2006, 00:00

  • PCN58 PRESCRIPTION MEDICATION COSTS TO PROSTATE CANCER PATIENTS- SURVEY RESPONSES COMPARED TO AN ADMINISTRATIVE REGISTER

    Nov 1, 2006, 00:00

  • PHP34 PHYSICIANS' ATTITUDES TO AND EXPERIENCE WITH INCREASED USE OF INDIVIDUAL REIMBURSEMENT VERSUS GENERAL REIMBURSEMENT OF NEW IMPORTANT PHARMACEUTICALS

    Nov 1, 2006, 00:00

  • PIH1 BUDGET IMPACT ANALYSIS OF AVODART (DUTASTERIDE) IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN POLAND

    Nov 1, 2006, 00:00

  • PMH38 A MODEL TO ASSESS THE COST-EFFECTIVENESS OF NEW TREATMENTS FOR DEPRESSION

    Nov 1, 2006, 00:00

  • ES5 RIMONABANT FOR THE TREATMENT OF OVERWEIGHT AND OBESE INDIVIDUALS AT INCREASED CARDIOMETABOLIC RISK-AN ECONOMIC EVALUATION USING DISCRETE EVENT SIMULATION

    Nov 1, 2006, 00:00

  • PRS5 COSTS OF COPD EXACERBATIONS IN POLAND (RESULTS OF THE PILOT STUDY)

    Nov 1, 2006, 00:00

  • PMH1 COST-EFFECTIVENESS OF CLINICALLY PROVEN TREATMENT STRATEGIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)- IMPACT OF COEXISTING CONDITIONS

    Nov 1, 2006, 00:00

  • PMC10 ESTIMATING UTILITY VALUES FOR HEALTH STATUS USING THE SPANISH VERSION OF THE SF-36. IS IT WORTHY TO CALCULATE WEIGHT VALUES FOR UTILITY MEASURES?

    Nov 1, 2006, 00:00

  • PCV11 CLINICAL EFFECTIVENESS OF BETALOC ZOC COMPARED TO METOPROLOL TARTRATE OR CARVEDILOL IN HYPERTENSION TREATMENT

    Nov 1, 2006, 00:00

  • PIH22 LINGUISTIC VALIDATION OF THE MENSTRUAL DISTRESS QUESTIONNAIRE (MDQ) IN AN INTERNATIONAL STUDY FOR A NEW COMBINED ORAL CONTRACEPTIVE PILL

    Nov 1, 2006, 00:00

  • PCN32 COST-MINIMIZATION ANALYSIS OF ORAL VS. IV FLUDARABINE FOR THE TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) IN BRAZIL

    Nov 1, 2006, 00:00

  • Impact of Rofecoxib Withdrawal on Cyclooxygenase-2 Utilization among Patients with and without Cardiovascular Risk

    Nov 1, 2006, 00:00

  • PDB8 THE IMPACT OF IMPROVED BETA-CELL FUNCTION ON MODELLING THE COST-EFFECTIVENESS OF ROSIGLITAZONE IN THE MANAGEMENT OF TYPE 2 DIABETES IN SPAIN

    Nov 1, 2006, 00:00

  • PGI10 COST-EFFECTIVENESS OF ESOMEPRAZOLE VERSUS GENERIC OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX ESOPHAGITIS IN GERMANY

    Nov 1, 2006, 00:00

  • PHP18 PRICES OF GENERIC DRUGS IN FINLAND VS. EUROPE

    Nov 1, 2006, 00:00

  • PDB45 EXPERIENCE OF HYPOGLYCEMIA IS SIGNIFICANTLY ASSOCIATED WITH LOWER QUALITY OF LIFE (EUROQOL) IN DIABETIC PATIENTS TREATED WITH METFORMIN (MF) IN COMBINATION WITH A SULPHONYLUREA (SU) IN FRANCE

    Nov 1, 2006, 00:00

  • DISCLOSURE INFORMATION

    Nov 1, 2006, 00:00

  • PCN43 COST-EFFECTIVENESS OF CETUXIMAB (ERBITUX®) IN COMBINATION WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CANCER IN FRANCE

    Nov 1, 2006, 00:00

  • PEY21 IMPACT OF BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND RELATED VISUAL IMPAIRMENT ON PATIENTS' QUALITY OF LIFE AND FUNCTIONING- A SURVEY OF FIVE COUNTRIES

    Nov 1, 2006, 00:00

  • PCN37 COMPARING MANAGEMENT PATTERNS AND ASSOCIATED COSTS FOR WOMEN WITH ABNORMAL CERVICAL CYTOLOGY IN 5 DIFFERENT COUNTRIES

    Nov 1, 2006, 00:00

  • PND12 A LITERATURE REVIEW OF PATIENT-REPORTED OUTOMES (PROS), NEUROPSYCHOLOGICAL AND COGNITIVE INSTRUMENTS IN PARKINSON'S DISEASE

    Nov 1, 2006, 00:00

  • PDB43 EFFECT OF INSULIN GLARGINE AND NPH ON QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Nov 1, 2006, 00:00

  • PUK12 DECISION MODEL OF RESOURCE (TIME) SAVINGS GENERATED BY EXTENDED DOSING OF ERYTHROPOIESIS STIMULATING PROTEIN (ESP) FOR THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS

    Nov 1, 2006, 00:00

  • PIH2 HEALTH ECONOMIC CONSEQUENCES OF THE CHOICE OF FOLLICLE STIMULATING HORMONE ALTERNATIVES IN IVF TREATMENT

    Nov 1, 2006, 00:00

  • PDB25 COST OF INPATIENT AND OUTPATIENT CARE OF SWEDISH PATIENTS WITH DIABETES MELLITUS

    Nov 1, 2006, 00:00

  • MC5 HUMANISTIC BURDEN AND HEALTH RESOURCE UTILIZATION AMONG NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS- RESULTS FOR GERMANY FROM A MULTI-COUNTRY CROSSSECTIONAL STUDY

    Nov 1, 2006, 00:00

  • PEY3 COMPARING EFFICACY OF PROSTAGLANDIN ANALOGUES FOR CONTROLLING INTRA-OCULAR PRESSURE (IOP)- RESULTS OF A META-ANALYSIS

    Nov 1, 2006, 00:00

  • PCN51 PHYSICIAN AND PATIENT CHARACTERISTICS ASSOCIATED WITH OUTPATIENT BREAST CANCER SCREENING RECOMMENDATIONS-ANALYSIS OF US OUTPATIENT DATA 1996–2004

    Nov 1, 2006, 00:00

  • POS3 KAPLAN-MEIER SURVIVAL ANALYSIS OF PATIENTS WITH MEDIAL AND LATERAL FEMORAL NECK FRACTURE OVER 60

    Nov 1, 2006, 00:00

  • PMH22 REHOSPITALIZATION RATES IN SCHIZOPHRENIA- COMPREHENSIVE LITERATURE REVIEW

    Nov 1, 2006, 00:00

  • PUK25 LINGUISTIC VALIDATION OF THE PATIENT PERCEPTION OF BLADDER CONDITION QUESTIONNAIRE (PPBC) IN 10 LANGUAGES

    Nov 1, 2006, 00:00

  • PUK2 LINKING CNI REGIMEN ADHERENCE TO HOSPITAL DAYS AND HEALTH CARE COSTS

    Nov 1, 2006, 00:00

  • PIH6 ECONOMIC EVALUATION OF CARBETOCINE FOR THE PREVENTION OF UTERINE ATONY IN PATIENTS WITH RISK FACTORS IN MEXICO

    Nov 1, 2006, 00:00

  • PCN7 IMPACT OF CHANGES IN THE FINANCING OF THE HEALTH SERVICES ON COSTS STRUCTURE ON THE EXAMPLE OF CHEMOTHERAPY OF ADVANCED OVARIAN CANCER

    Nov 1, 2006, 00:00

  • PCN63 ADVANCED CUTANEOUS MALIGNANT MELANOMA- SYSTEMATIC REVIEW OF PHARMACOECONOMIC AND QUALITY OF LIFE STUDIES

    Nov 1, 2006, 00:00

  • PIN13 ECONOMIC EVALUATION OF EARLY MONOTHERAPY WITH INTERFERON VERSUS DELAYED COMBINATION THERAPY WITH INTERFERON AND RIBAVIRIN IN PATIENTS WITH ACUTE HEPATITIS C

    Nov 1, 2006, 00:00

  • PDB49 TREATMENT SATISFACTION WITH INSULIN GLARGINE AND INSULIN GLULISINE IN DIABETES MELLITUS-EVALUATED IN AN OBSERVATIONAL STUDY IN GERMANY

    Nov 1, 2006, 00:00

  • PST1 BUDGETARY IMPACT ANALYSIS OF RECOMBINANT ACTIVATED FACTOR VII IN THE TREATMENT OF INTRACEREBRAL HEMORRHAGE- A US HEALTH PLAN PERSPECTIVE

    Nov 1, 2006, 00:00

  • PND1 META-ANALYSIS OF THE EFFICACY AND TOLERABILITY OF PRAMIPEXOLE AND ROPINIROLE IN RESTLESS LEGS SYNDROME (RLS)

    Nov 1, 2006, 00:00

  • Too Much Ado about Propensity Score Models? Comparing Methods of Propensity Score Matching

    Nov 1, 2006, 00:00

  • PIN17 THE COST-EFFECTIVENESS OF A MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE IN GERMANY

    Nov 1, 2006, 00:00

  • MC7 TRANSLATION AND VALIDATION OF NEW LANGUAGE VERSIONS OF THE ANKYLOSING SPONDYLITIS QUALITY OF LIFE (ASQOL) QUESTIONNAIRE

    Nov 1, 2006, 00:00

  • GI1 COST OF FUNCTIONAL DYSPEPSIA-RESULTS FROM A LARGE US EMPLOYER DATABASE

    Nov 1, 2006, 00:00

  • PMH8 BUDGET IMPACT MODEL FOR DETERMINING THE COSTS OF INTRODUCING ZIPRASIDONE FOR THE MANAGEMENT OF ACUTE BIPOLAR MANIA IN SPAIN

    Nov 1, 2006, 00:00

  • PHP27 THE ANALYSIS OF TEMPORARY WORK DISABILITY FOR THE PERIOD OF OVER 30 DAYS IN THE REPUBLIC OF SERBIA

    Nov 1, 2006, 00:00

  • HP3 THE ROLE OF GENERAL PRACTITIONERS IN THE INITIAL MANAGEMENT OF WOMEN WITH URINARY INCONTINENCE IN FRANCE, GERMANY, SPAIN AND THE UK

    Nov 1, 2006, 00:00

  • PUK14 A COST-UTILITY ANALYSIS IN A UK SETTING OF CINACALCET FOR SECONDARY HYPERPARATHYROIDISM IN END STAGE RENAL DISEASE

    Nov 1, 2006, 00:00

  • ES3 PROCESS OPTIMIZATION IN A 10-BED INTENSIVE CARE UNIT (ICU) IN GERMANY- IMPACT ON CASE-RELATED TREATMENT COSTS

    Nov 1, 2006, 00:00

  • ES4 SYSTEMATIC REVIEW OF BUDGET IMPACT ANALYSES

    Nov 1, 2006, 00:00

  • PHP32 PATIENT SATISFACTION WITH THE PHARMACY FIRST MINOR AILMENTS SCHEME

    Nov 1, 2006, 00:00

  • PHP11 DOSE DISPENSED MEDICINE AND ASSOCIATED MEDICINE AND HEALTH CARE COST

    Nov 1, 2006, 00:00

  • PCV82 VALIDATION OF A MODEL TO PREDICT LIFETIME CLINICAL AND ECONOMIC BENEFIT OF RAISING HDL-C IN STATINTREATED PATIENTS WITH PERSISTENTLY LOW HDL-C

    Nov 1, 2006, 00:00

  • PIN31 HEALTH RELATED QUALITY OF LIFE IN CHRONIC HEPATITIS B PATIENTS

    Nov 1, 2006, 00:00

  • PCV22 COST IMPACT OF DIAGNOSTIC IMAGING FOR LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE (PVD)

    Nov 1, 2006, 00:00

  • PMH42 QUALITY OF LIFE IN PATIENTS WITH BIPOLAR DISORDER IN 5 EUROPEAN COUNTRIES

    Nov 1, 2006, 00:00

  • POS13 THE ESTIMATION OF COST–EFFECTIVENESS THRESHOLDS PRIOR TO THE START OF LARGE CLINICAL STUDIES

    Nov 1, 2006, 00:00

  • PUK17 USE OF SIMULATION TO CAPTURE THE MULTIFACTORIAL ASPECTS OF RENAL DISEASE

    Nov 1, 2006, 00:00

  • PHP14 STAKEHOLDERS' PERSPECTIVES ON IMPROVING ACCESS TO PRIMARY CARE

    Nov 1, 2006, 00:00

  • PMH33 STRUCTURAL EQUATION MODELLING OF SCHIZOPHRENIA EARLY RETIREMENT IN GERMANY

    Nov 1, 2006, 00:00

  • PIH21 INFLUENCE OF CONCOMITANT DISEASES ON THE CLINICAL RESPONSE TO TREATMENT FOR ERECTILE DYSFUNCTION

    Nov 1, 2006, 00:00

  • PIN10 COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) FOR THE TREATMENT OF CHRONIC HEPATITIS B IN ITALY

    Nov 1, 2006, 00:00

  • PDB48 MANAGEMENT AND TREATMENT ADHERENCE IN TYPE 2 DIABETIC PATIENTS IN SPAIN

    Nov 1, 2006, 00:00

  • OA3 HOW DO PRESCRIBERS ACT WHEN A PRODUCT IS WITHDRAWN FROM THE MARKET? FIRST LESSONS FROM THE COX-2 INHIBITORS PATIENTS POST ROFECOXIB STUDY (CIPRES)

    Nov 1, 2006, 00:00

  • PHP5 THE PHARMACEUTICAL INDUSTRY PERSPECTIVE ON PHARMACOECONOMICS IN SAUDI ARABIA

    Nov 1, 2006, 00:00

  • PCV43 COST ANALYSIS OF TREATMENT WITH NESIRITIDE FOR ACUTE DECOMPENSATED HEART FAILURE IN A BRAZILIAN SETTING

    Nov 1, 2006, 00:00

  • CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRA ...

    Nov 1, 2006, 00:00

  • PRS17 VALIDATION OF THE COPD SEVERITY SCORE FOR USE IN THE SPANISH PRIMARY HEALTH CARE SYSTEM, THE NEREA STUDY- PRELIMINARY RESULTS

    Nov 1, 2006, 00:00

  • PMH29 ACUTE HOSPITALIZATION IN THE ELDERLY-RELATIONSHIP WITH PSYCHIATRIC MORBIDITY AND SOCIAL EQUITY IN HEALTH CARE ACESS IN SINGAPORE

    Nov 1, 2006, 00:00

  • PUK4 AN ECONOMIC EVALUATION OF DE NOVO RENAL TRANSPLANT RECIPIENTS USING BRANDED (B-CSA) VS. NON-BRANDED CYCLOSPORINE MODIFIED (NB-CSA)

    Nov 1, 2006, 00:00

  • PDB13 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN IN THE UK IN PEOPLE WITH TYPE 2 DIABETES

    Nov 1, 2006, 00:00

  • PMH24 ASSESSMENT OF RESOURCE UTILISATION IN ADULTS DIAGNOSED WITH DEPRESSION IN THE UK-A GPRD-BASED STUDY

    Nov 1, 2006, 00:00

  • PPN4 ECONOMIC EVALUATION COMPARING BMP-2 (INDUCTOSTM) VERSUS CURRENT TREATMENT IN CHRONIC LOWER BACK PAIN IN THE SPANISH SETTING

    Nov 1, 2006, 00:00

  • PMH18 DIRECT COST OF DEPRESSION–ANALYSIS OF A GERMAN CLAIMS DATABASE

    Nov 1, 2006, 00:00

  • PCV49 COST-UTILITY ANALYSIS USING A MARKOV MODEL TO COMPARE PRESCRIPTION STATINS VERSUS POTENTIAL OVER THE COUNTER STATINS IN USA

    Nov 1, 2006, 00:00

  • PAA5 ECONOMIC EVALUATION OF A NEW AIRWAY INFLAMMATION MONITOR IN THE DIAGNOSIS AND MANAGEMENT OF ASTHMA IN GERMANY

    Nov 1, 2006, 00:00

  • PGI13 ECONOMIC EVALUATION OF THE ARTIFICIAL LIVER SUPPORT SYSTEM MARS IN PATIENTS WITH ACUTE-ONCHRONIC LIVER FAILURE-FINAL RESULTS OF A CLINICAL COHORT TRIAL

    Nov 1, 2006, 00:00

  • PDB44 EXPLORING DIFFERENCES IN PATIENT VERSUS PUBLIC PREFERENCES IN HEALTH UTILITIES-A QUALITATIVE STUDY

    Nov 1, 2006, 00:00
  • «
  • 161
  • 162
  • 163 (current)
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • »